acetonitrile–water (1 : 1) (6 mL). The reaction mixture was stirred
at room temperature for 3 days, before being poured into a
saturated aqueous solution of NaHCO3. The aqueous layer was
extracted with ethyl acetate (3 × 5 mL), and the combined organic
extracts were dried (MgSO4), and concentrated under reduced
pressure. Recrystallization (ethyl acetate–hexanes) of the residue
gave 69 mg (70%) of compound 6.
(d) The Chemistry of b-Lactams, ed. M. I. Page, Chapman and Hall,
London, 1992; (e) Chemistry and Biology of b-Lactam Antibiotics, ed.
R. B. Morin and M. Gorman, Academic, New York, 1982, vols 1–3.
2 For selected reviews, see: (a) J. W. Clader, J. Med. Chem., 2004, 47, 1;
(b) G. Veinberg, M. Vorona, I. Shestakova, I. Kanepe and E. Lukevics,
Curr. Med. Chem., 2003, 10, 1741; for selected examples, see; (c) P. C.
Hogan and E. J. Corey, J. Am. Chem. Soc., 2005, 127, 15386; (d) L.
Kvaerno, T. Ritter, M. Werder, H. Hauser and E. M. Carreira, Angew.
Chem., Int. Ed., 2004, 43, 4653; Angew. Chem.20041164753; (e) D. A.
Burnett, Curr. Med. Chem., 2004, 11, 1873; (f) M. I. Page and A. P.
Laws, Tetrahedron, 2000, 56, 5631; (g) T. M. Haley, S. J. Angier, A. D.
Borthwick, R. Singh and R. G. Micetich, Drugs, 2000, 3, 512.
3 It has been reported that b-lactams act to modulate the expression of
glutamate neurotransmitter transporters via gene activation. See: J. D.
Rothstein, S. Patel, M. R. Regan, C. Haenggeli, Y. H. Huang, D. E.
Bergles, L. Jin, M. D. Hoberg, S. Vidensky, D. S. Chung, S. V. Toan,
L. I. Bruijn, Z.-z. Su, P. Gupta and P. B. Fisher, Nature, 2005, 433, 73.
4 For reviews, see: (a) B. Alcaide, P. Almendros and C. Aragoncillo,
Chem. Rev., 2007, 107, 4437; (b) B. Alcaide and P. Almendros, Curr.
Med. Chem., 2004, 11, 1921; (c) A. R. A. S. Deshmukh, B. M. Bhawal,
D. Krishnaswamy, V. V. Govande, B. A. Shinkre and A. Jayanthi,
Curr. Med. Chem., 2004, 11, 1889; (d) B. Alcaide and P. Almendros,
Synlett, 2002, 381; (e) C. Palomo, J. M. Aizpurua, I. Ganboa and M.
Oiarbide, Synlett, 2001, 1813; (f) B. Alcaide and P. Almendros, Chem.
Soc. Rev., 2001, 30, 226; (g) C. Palomo, J. M. Aizpurua, I. Ganboa and
M. Oiarbide, Amino Acids, 1999, 16, 321; (h) I. Ojima and F. Delaloge,
Chem. Soc. Rev., 1997, 26, 377; (i) M. S. Manhas, D. R. Wagle, J. Chiang
and A. K. Bose, Heterocycles, 1988, 27, 1755.
Fused bicyclic 2-azetidinone 6
Colorless solid; mp: 133–135 ◦C (hexanes–ethyl acetate); [a]D
=
+17.5 (c 1.0 in CH3OH); 1H NMR (300 MHz, acetone-d6, 25 ◦C):
d = 7.46 (d, J = 9.2 Hz, 2H), 6.98 (m, 2H), 4.59 (d, J = 3.9 Hz, 1H),
4.45 (t, J = 3.4 Hz, 1H), 4.22 (m, 2H), 3.90 (dd, J = 11.2, 3.4 Hz,
1H), 3.79 (s, 3H); 13C NMR (acetone-d6): d = 163.9, 157.0, 131.0,
118.6, 114.9, 113.2, 74.2, 70.3, 64.5, 55.3; IR (CHCl3): m = 3325,
1744 cm−1; MS (EI): m/z (%): 251 (29) [M]+, 134 (100); elemental
analysis calcd (%) for C12H13NO5 (251.1): C 57.37, H 5.22, N 5.58;
found C 56.95, H 5.06, N 5.25.
Dehydrobromination reaction of 3-[bromonitromethyl]-3-hydroxy-
b-lactam 2a. Preparation of spirocyclic b-lactam 7
5 (a) C. J. Unkefer, R. E. London, R. D. Durbin, T. F. Uchytil and P. J.
Langston-Unkefer, J. Biol. Chem., 1987, 262, 4993; (b) T. D. Meek and
J. V. Villafranca, Biochemistry, 1980, 19, 5513; (c) S. L. Sinden and
R. D. Durbin, Nature, 1968, 219, 379.
6 F. Benfatti, G. Cardillo, L. Gentilucci, R. Perciaccante, A. Tolomelli
and A. Catapano, J. Org. Chem., 2006, 71, 9229.
7 A. Imada, K. Kitano, K. Kintana, M. Muroi and M. Asai, Nature,
1981, 289, 590.
8 (a) R. E. Dolle, M. J. Hughes, C.-S. Li and L. I. Kruse, J. Chem. Soc.,
Chem. Commun., 1989, 1448; (b) W. J. Greenlee, J. P. Springer and A. A.
Patchett, J. Med. Chem., 1989, 32, 165; (c) J. E. Baldwin, M. Otsuka and
P. M. Wallace, Tetrahedron, 1986, 42, 3097; (d) W. W. Stewart, Nature,
1971, 229, 174.
Potassium carbonate (65 mg, 0.47 mmol) was added to a stirred so-
lution of bromonitroalcohol 2a (168 mg, 0.39 mmol) in methanol
(5 mL). The reaction mixture was stirred at room temperature
for 5 h, before being poured into a saturated aqueous solution of
NH4Cl. The aqueous layer was extracted with ethyl acetate (3 ×
5 mL), and the combined organic extracts were dried (MgSO4),
and concentrated under reduced pressure. Chromatography of the
residue eluting with hexanes–ethyl acetate (3 : 1) gave 82 mg (60%)
of compound 7.
9 As an example, (2R,3S)-3-amino-2-hydroxy-5-methylhexanoic acid
(norstatine) and (3R,4S)-4-amino-3-hydroxy-5-methylheptanoic acid
(statine) are residues for peptide inhibitors of enzymes, such as renin
and HIV-1 protease; see: (a) S. Thaisrivongs, D. T. Pals, L. T. Kroll,
S. R. Turner and F.-S. Han, J. Med. Chem., 1987, 30, 976; (b) J. R. Huff,
J. Med. Chem., 1991, 34, 2305; moreover, phenylisoserine analogues are
used to synthesize new taxoids; (c) C. Lucatelli, F. Viton, Y. Gimbert
and A. E. Greene, J. Org. Chem., 2002, 67, 9468; (d) I. Ojima, T. Wang
and F. Delaloge, Tetrahedron Lett., 1998, 39, 3663; (e) I. Ojima, S. D.
Kuduk, P. Pera, J. M. Veith and R. J. Bernacki, J. Med. Chem., 1997,
40, 267.
10 For selected reviews, see: (a) C. Palomo, M. Oiarbide and A. Laso,
Eur. J. Org. Chem., 2007, 2561; (b) J. Boruwa, N. Gogoi, P. P. Saikia and
N. C. Barua, Tetrahedron: Asymmetry, 2006, 17, 3315; (c) C. Palomo,
M. Oiarbide and A. Mielgo, Angew. Chem., Int. Ed., 2004, 43, 5442;
(d) F. A. Luzzio, Tetrahedron, 2001, 57, 915.
Spirocyclic 2-azetidinone 7
Colorless solid; mp: 71–73 ◦C (hexanes–ethylacetate);[a]D = +42.4
(c 0.5 in CH2Cl2); 1H NMR (300 MHz, CDCl3, 25 ◦C): d = 7.49
and 6.90 (d, J = 9.3 Hz, each 2H), 5.77 (s, 1H), 4.56 (m, 1H),
4.40 (d, J = 5.4 Hz, 1H), 4.25 and 4.00 (dd, J = 9.3, 6.5 Hz, each
1H), 3.81 (s, 3H), 1.40 and 1.37 (s, each 3H); 13C NMR (CDCl3):
d = 158.9, 157.4, 130.1, 120.0, 114.3, 110.2, 78.4, 75.4, 69.3, 66.1,
60.9, 55.4, 26.2, 25.3; IR (CHCl3): m = 1745, 1557 cm−1; MS (EI):
m/z (%): 350 (64) [M]+, 101 (100); elemental analysis calcd (%) for
C16H18N2O7 (350.3): C 54.86, H 5.18, N 8.00; found C 54.47, H
5.05, N 7.85.
11 For antibacterial or biocide activities, see: (a) N. G. Clark, B. Croshaw,
B. E. Leggetter and D. F. Spooner, J. Med. Chem., 1974, 17, 977;
(b) N. G. Clark, B. Croshaw, D. F. Spooner (Boots Pure Drug
Co., Ltd.), English Patent Application, GB 1057131, 1967; Chem.
Abstr.196766104675; (c) T. Yamada (Konishiroku Photo Industry Co.,
Ltd., Japan), Japanese Patent Application, JP 08134371 A2, 1996; Chem.
Abstr.1996125208284; for industrial ink-derived uses, see; (d) K. Mine,
Y. Kobayashi, Y. Kawaguchi, S. Aoki (Konishiroku Photo Industry Co.,
Ltd., Japan), Japanese Patent Application, JP 61055173 A2, 1986; Chem.
Abstr.198610599202; (e) S. Hirabayashi (Konishiroku Photo Industry
Co., Ltd., Japan), Japanese Patent Application, JP 07140620 A2, 1995;
Chem. Abstr.1995123241899.
12 J. M. Concello´n, H. Rodr´ıguez-Solla, C. Concello´n, S. Garc´ıa-Granda
and M. R. D´ıaz, Org. Lett., 2006, 8, 5979.
13 See, for instance: (a) B. Alcaide, P. Almendros and T. Mart´ınez del
Campo, Angew. Chem., Int. Ed., 2007, 46, 6684; (b) B. Alcaide,
P. Almendros, T. Mart´ınez del Campo and R. Rodr´ıguez-Acebes,
Adv. Synth. Catal., 2007, 349, 749; (c) B. Alcaide, P. Almendros, C.
Acknowledgements
Support for this work by the Direccio´n General de Investi-
gacio´n, Ministerio de Educacio´n y Ciencia (DGI-MEC) (Project
CTQ2006–10292), Comunidad Auto´noma de Madrid (CCG-
07-UCM/PPQ-2308 and Universidad Complutense de Madrid
(Grant GR74/07) are gratefully acknowledged.
References and notes
1 See, for example: (a) D. Niccolai, L. Tarsi and R. J. Thomas, Chem.
Commun., 1997, 2333; (b) R. Southgate, Contemp. Org. Synth., 1994,
1, 417; (c) R. Southgate, C. Branch, S. Coulton, E. Hunt, in Recent
Progress in the Chemical Synthesis of Antibiotics and Related Microbial
Products, ed. G. Lukacs, Springer, Berlin, 1993, vol. 2, pp. 621;
This journal is
The Royal Society of Chemistry 2008
Org. Biomol. Chem., 2008, 6, 1635–1640 | 1639
©